POS1238 EVALUATING OUTCOMES FOR PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH OBINUTUZUMAB, A HUMANISED ANTI-CD20 MONOCLONAL ANTIBODY, FOLLOWING SECONDARY NON-DEPLETION OF B CELLS AND NON-RESPONSE WITH RITUXIMAB
M. Leandro(University College Hospital), Michael R. Ehrenstein, Corinne Fisher(University College Hospital), Venkat Reddy(University College London), Coziana Ciurtin(University College Hospital), Ruth J. Pepper(University College Hospital)
Cited by 0
Related Papers
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
|Annals of the Rheumatic Diseases|2013|454
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
|Lara D. Veeken|2003|367
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
|Nephrology Dialysis Transplantation|2009|156